STOCK TITAN
  1. Home
  2. Sec-filings
  3. INAB
  4. [8-K] IN8BIO, INC. Reports Material Event

IN8bio (Nasdaq: INAB) reports Q2 loss and GBM clinical data

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

IN8bio, Inc., a clinical-stage biopharmaceutical company focused on γδ T cell therapies, reported results for the second quarter ended June 30, 2026. The company recorded a net loss of $4.8 million, or $0.25 per share, compared with a net loss of $5.1 million, or $1.24 per share, a year earlier. Research and development expenses were $2.5 million and general and administrative expenses were $2.4 million. Cash was $18.0 million as of June 30, 2026, compared with $13.2 million in the prior-year period.

IN8bio highlighted progress across its pipeline, including advancing INB-619, a CD19-targeting γδ T cell engager, into IND-enabling studies, with initial in vivo preclinical data expected in the second half of 2026. Updated data from the DeltEx DRI glioblastoma program showed median progression-free survival of 13.0 months versus 6.6 months for standard-of-care and median overall survival exceeding 19.5 months versus 13.2 months. Additional translational analyses showed an 18-fold increase in intratumoral CD8+ T cells and a 90% reduction in immunosuppressive granulocytes after repeated DeltEx DRI dosing.

Positive

  • None.

Negative

  • None.

Filing Explained

At June 30, 2026, cash was $17,956 thousand and 9,853,121 common shares were outstanding, versus $27,092 thousand and 9,766,132 at year-end.

Form 8-K reports specified material events; Item 2.02 here covers results of operations and financial condition. On August 6, 2026, IN8BIO furnished its unaudited second-quarter results for the period ended June 30, 2026.

The period-end balance sheet reports cash of $17,956 thousand, down from $27,092 thousand at December 31, 2025, and 9,853,121 issued and outstanding common shares, up from 9,766,132. For existing common holders, the visible structural change is a lower reported cash balance and a larger issued share base, although the filing does not identify the cause of the share-count change.

The filing separately reports 490,000,000 authorized common shares and does not state a transaction-specific dilution percentage or proceeds amount, so the share-count change cannot be tied to a financing from this disclosure alone.

The next named resolution path is a future company report on FDA discussions concerning potential regulatory pathways for the DeltEx DRI glioblastoma program.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Net loss, Q2 2026 $4.8 million Three months ended June 30, 2026, compared with $5.1 million a year earlier
Net loss per share, Q2 2026 $0.25 per basic and diluted share Three months ended June 30, 2026, versus $1.24 in the prior-year quarter
Cash balance $18.0 million As of June 30, 2026, compared with $13.2 million in the comparable prior-year period
R&D expenses, Q2 2026 $2.5 million Three months ended June 30, 2026, similar to $2.5 million in Q2 2025
G&A expenses, Q2 2026 $2.4 million Three months ended June 30, 2026, versus $2.7 million in Q2 2025
Median progression-free survival with DeltEx DRI 13.0 months Repeat-dose newly diagnosed GBM patients versus 6.6 months for standard-of-care
Median overall survival with DeltEx DRI Exceeding 19.5 months Newly diagnosed GBM repeat-dose patients versus 13.2 months for standard-of-care
Increase in intratumoral CD8+ T cell density 18-fold Observed in spatial proteomics after repeated DeltEx DRI dosing in GBM
gamma-delta (γδ) T cell engagers medical
"developing innovative gamma-delta (γδ) T cell therapies and γδ T cell engagers"
cytokine release syndrome (CRS) medical
"potentially reducing toxicities including cytokine release syndrome (CRS) and infections"
An excessive immune reaction in which the body’s defense system releases large amounts of inflammatory signals (cytokines) all at once, like an overactive alarm system that triggers too many responders and causes collateral damage. It matters to investors because this side effect can halt clinical trials, prompt safety warnings or recalls, and increase development costs and regulatory scrutiny for drugs or therapies, affecting a company’s valuation and future revenue prospects.
median progression-free survival (mPFS) medical
"more than doubled expected median progression-free survival (mPFS) in newly diagnosed GBM"
Median progression-free survival is the middle value of time, in a group of patients in a clinical trial, during which their disease does not get worse after starting a treatment — half the patients went longer without progression and half progressed sooner. Investors use it as an early measure of a drug’s effectiveness and commercial promise, because longer progression-free times can signal stronger clinical benefit, higher chances of regulatory approval, and greater market value, even though it is not the same as overall survival.
right-of-use assets financial
"Right-of-use assets - operating leases"
Right-of-use assets are the rights a company gains to use a physical space or equipment under a lease agreement. They are recorded as assets on the company's balance sheet, reflecting the value of future benefits from the leased item. For investors, these assets provide a clearer picture of a company's obligations and resources related to leasing arrangements, helping to assess its financial health and operational commitments.
haploidentical stem cell transplantation medical
"for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation"
Net loss $4.8 million Compared with $5.1 million for the three months ended June 30, 2025
Net loss per share, basic and diluted $0.25 Compared with $1.24 for the three months ended June 30, 2025
Research and development expenses $2.5 million Compared with $2.5 million for the three months ended June 30, 2025
General and administrative expenses $2.4 million Compared with $2.7 million for the three months ended June 30, 2025

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What were IN8bio (INAB)'s key financial results for Q2 2026?
IN8bio reported a net loss of $4.8 million, or $0.25 per share, for Q2 2026. Research and development expenses were $2.5 million and general and administrative expenses were $2.4 million, with interest income of $154,000 during the quarter.

How much cash did IN8bio (INAB) hold as of June 30, 2026?
As of June 30, 2026, IN8bio held $18.0 million in cash, up from $13.2 million in the comparable prior-year period. The balance sheet showed total assets of $21.7 million and stockholders’ equity of $18.4 million at that date.

What glioblastoma (GBM) clinical results did IN8bio (INAB) report for DeltEx DRI?
IN8bio reported DeltEx DRI data in newly diagnosed GBM showing median progression-free survival of 13.0 months versus 6.6 months for standard-of-care and median overall survival exceeding 19.5 months versus 13.2 months. About 43% of repeat-dose patients were alive at 24 months, versus 20% for standard-of-care.

What progress did IN8bio (INAB) make on its INB-619 γδ T cell engager?
INB-619, a CD19-targeting γδ T cell engager, moved into IND-enabling studies after preclinical data showed complete B cell depletion, robust γδ T cell expansion, and minimal CRS-associated cytokine release. IN8bio expects initial in vivo preclinical data for INB-619 in the second half of 2026.

What upcoming milestones did IN8bio (INAB) highlight?
Planned milestones include initial INB-619 preclinical animal data in the second half of 2026, FDA discussions on regulatory pathways for the DeltEx DRI GBM program, an INB-100 clinical update at a scientific meeting in late 2026, and further DeltEx DRI clinical and translational updates.

How did IN8bio (INAB)'s operating expenses change year over year in Q2 2026?
Total operating expenses were $4.9 million in Q2 2026, slightly below $5.2 million in Q2 2025. Research and development expenses were stable at $2.5 million, while general and administrative expenses declined to $2.4 million from $2.7 million in the prior-year quarter.
false000174027900017402792026-08-062026-08-06

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 06, 2026

 

 

IN8bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39692

82-5462585

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

350 5th Avenue, Suite 5330

 

New York, New York

 

10118

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 646 600-6438

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

INAB

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition.

On August 6, 2026, IN8bio, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

d) Exhibits.

 

Exhibit No.

 

Description

99.1

 

Press Release, dated August 6, 2026.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

IN8bio, Inc.

Date:

August 6, 2026

By:

/s/ Patrick McCall

Patrick McCall

 

Chief Financial Officer and Secretary

(Principal Financial and Accounting Officer)

 

Exhibit 99.1

 

IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

•
Advanced next-generation gamma delta (γδ) T cell engager (TCE) platform demonstrating a novel mechanism for γδ T cell expansion, deep target cell depletion, and favorable cytokine profile; Initial in vivo data expected in the second half of 2026
•
Presented updated data at ASCO 2026 demonstrating median overall survival (mOS) exceeding 19.5 months and still climbing, across all patients with newly diagnosed glioblastoma (GBM) treated with repeat-dosing of DeltEx™ Drug Resistant Immunotherapy (DRI)
•
Published peer-reviewed clinical data from Phase 1 INB-200 trial in The Journal of Clinical Oncology (JCO) demonstrating DeltEx™ DRI more than doubled expected median progression-free survival (mPFS) in newly diagnosed GBM
•
Reported new translational AI proteomic and immunogenomic analyses demonstrating DeltEx DRI preserves immune function and positively remodels the GBM tumor microenvironment, providing additional evidence supporting its therapeutic efficacy potential

NEW YORK, August 6, 2026 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for cancer and autoimmune diseases, today reported financial results and business highlights for the second quarter ended June 30, 2026.

“The second quarter marked an important period of scientific and clinical validation for γδ T cell therapeutics and IN8bio. Our γδ TCE platform is progressing, with INB-619 advancing into initial animal models. We are pleased to remain on track for reporting initial in vivo data this year,” said William Ho, Chief Executive Officer and co-founder of IN8bio. “In addition, peer-reviewed and updated clinical data from our glioblastoma program continue to demonstrate a favorable safety profile and provide strong evidence that γδ T cells are clinically active and can be delivered safely to potentially improve patient outcomes. We remain focused on disciplined execution, as we continue to seek a regulatory pathway for our glioblastoma program, with the ultimate goal of bringing much needed treatment to patients.”

Advancing Next-Generation γδ TCE Platform (INB-619)

•
Continued advancement of proprietary INB-600 platform of novel γδ T cell engagers, designed to selectively eliminate targets such as CD19, potentially reducing toxicities including cytokine release syndrome (CRS) and infections, while expanding the therapeutic window compared with conventional CD3-targeting T cell engagers.

 

•
Advancing INB-619, a CD19-targeting γδ T cell engager for oncology and autoimmune diseases, into IND-enabling studies following encouraging early preclinical data demonstrating complete B cell depletion, robust γδ T cell expansion, and minimal CRS-associated cytokine release, including IL-6 and TNF-α.
•
Remain on track to report initial in vivo preclinical data in the second half of 2026.

Reported Clinical and Translational Advances for DeltEx™ DRI in Newly Diagnosed Glioblastoma

During the second quarter, IN8bio reported multiple clinical and scientific milestones supporting the clinical activity of γδ T cells and IN8bio’s DeltEx™ DRI platform:

•
Published the first peer-reviewed clinical results of DeltEx DRI in newly diagnosed GBM in The Journal of Clinical Oncology. Among all patients treated, no dose-limiting toxicities (DLTs), CRS or immune effector cell-associated neurotoxicity syndrome (ICANS) were observed.
•
Presented updated clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating encouraging survival benefit in repeat-dose treated patients, with mPFS of 13.0 months versus 6.6 months for contemporaneously enrolled patients receiving only standard-of-care (SOC) and mOS exceeding 19.5+ months versus 13.2 months for SOC.
•
Approximately 43% of repeat-dose patients remained alive at 24 months compared with 20% of SOC patients.
•
Presented new translational data at the International Society for Cell & Gene Therapy (ISCT) and International Society for Cell & Gene Therapy (ISCT) and American Society of Gene & Cell Therapy (ASGCT) Annual Meetings integrating artificial intelligence (AI), immunogenomics, histopathology, transcriptomics and spatial proteomics. Repeated DeltEx™ DRI dosing demonstrated preserved immune function during chemotherapy and positively remodeled the glioblastoma tumor microenvironment.
•
Spatial proteomics analyses demonstrated an 18-fold increase in intratumoral CD8+ T cell density and a 90% reduction in immunosuppressive granulocytes, providing mechanistic support for the clinical activity observed with DeltEx™ DRI.

 

 

•
IN8bio Chief Scientific Officer Lawrence Lamb co-authored a review in Nature Communications highlighting advances in γδ T cell engineering, γδ T cell engagers, CAR γδ T cells and combination immunotherapy strategies, reinforcing IN8bio's scientific leadership in the rapidly expanding γδ T cell field.
•
The publication highlights the potential of “off-the-shelf” γδ T cell therapies, driven by the cells’ lack of graft-versus-host disease (GvHD), and the growing clinical evidence supporting their application across hematologic malignancies and solid tumors, including GBM.

Upcoming Anticipated Milestones

•
Report initial preclinical animal data for INB-619 in the second half of 2026.
•
Report on FDA discussions regarding the potential regulatory pathways for the DeltEx™ DRI GBM program.
•
INB-100 program clinical update at a scientific meeting in late 2026.
•
Provide additional clinical and translational updates from the DeltEx™ DRI GBM program.

Second Quarter 2026 Financial Highlights

•
Cash position: As of June 30, 2026, the Company had cash of $18.0 million, compared with $13.2 million, for the comparable prior year period.
•
Research and Development (R&D) expenses: R&D expenses were $2.5 million for the three months ended June 30, 2026, compared with $2.5 million for the comparable prior year period. These amounts include non-cash items such as stock-based compensation (SBC) and depreciation.
•
General and administrative (G&A) expenses: G&A expenses were $2.4 million for the three months ended June 30, 2026, compared with $2.7 million for the comparable prior year period. These amounts include non-cash items such as SBC and depreciation.
•
Net loss: The Company reported a net loss of $4.8 million, or $0.25 per basic and diluted common share, for the three months ended June 30, 2026, compared with a net loss of $5.1 million, or $1.24 per basic and diluted common share, for the comparable prior year period.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical

 

 

stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.

Forward Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential of IN8bio’s product candidates; the potential of IN8bio’s INB-600 platform to improve durability and safety compared with traditional CD3-targeting engagers; IN8bio’s ability to achieve anticipated milestones, including receipt of guidance from the FDA on regulatory pathways for the DeltEx™ DRI GBM program, expected presentations and data readouts from its preclinical studies and clinical trials including preclinical in vivo data for INB-619, patient dosing timelines and advancement of clinical development plans; and other statements that are not historical fact. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio’s ability to meet anticipated deadlines and milestones; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio’s product candidates; the risk that IN8bio may be unable to raise additional capital and could be forced to delay, further reduce or to explore other strategic options for certain of its development programs, or even terminate its operations; IN8bio’s ability to continue to operate as a going concern; the risk that IN8bio may not realize the intended benefits of its DeltEx platform and TCE program; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio’s product candidates; the uncertainty of regulatory approvals to conduct trials or to market products; IN8bio’s reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause IN8bio’s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section entitled “Risk Factors” in IN8bio’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 7, 2026, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

 

 

Investors and Corporate Contact:

IN8bio, Inc.

Patrick McCall

646.933.5603

pfmccall@IN8bio.com

Media Contact

Kimberly Ha

KKH Advisors

917.291.5744

kimberly.ha@kkhadvisors.com

 

 

IN8BIO, INC.

BALANCE SHEETS

(In thousands, except share and per share data)

 

 

 

June 30,

 

 

 

 

 

 

2026

 

 

December 31,

 

 

 

(unaudited)

 

 

2025

 

Assets

 

 

 

 

(Note 2)

 

Current assets

 

 

 

 

 

 

Cash

 

$

17,956

 

 

$

27,092

 

Prepaid expenses and other current assets

 

 

540

 

 

 

788

 

Total Current Assets

 

 

18,496

 

 

 

27,880

 

Non-current assets

 

 

 

 

 

 

Property and equipment, net

 

 

1,600

 

 

 

1,858

 

Restricted cash

 

 

176

 

 

 

220

 

Right-of-use assets - finance leases

 

 

125

 

 

 

296

 

Right-of-use assets - operating leases

 

 

1,246

 

 

 

1,882

 

Other non-current assets

 

 

102

 

 

 

146

 

Total Non-Current Assets

 

 

3,249

 

 

 

4,402

 

Total Assets

 

$

21,745

 

 

$

32,282

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

Accounts payable

 

$

444

 

 

$

309

 

Accrued expenses and other current liabilities

 

 

761

 

 

 

1,633

 

Short-term finance lease liability

 

 

126

 

 

 

295

 

Short-term operating lease liability

 

 

923

 

 

 

924

 

Total Current Liabilities

 

 

2,254

 

 

 

3,161

 

Long-term operating lease liability

 

 

1,128

 

 

 

1,563

 

Total Non-Current Liabilities

 

 

1,128

 

 

 

1,563

 

Total Liabilities

 

 

3,382

 

 

 

4,724

 

Stockholders' Equity

 

 

 

 

 

 

Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; no shares issued and outstanding

 

 

—

 

 

 

—

 

Common stock, par value $0.0001 per share; 490,000,000 shares authorized at June 30, 2026 and December 31, 2025; 9,853,121 and 9,766,132 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively

 

 

10

 

 

 

10

 

Additional paid-in capital

 

 

169,320

 

 

 

168,644

 

Accumulated deficit

 

 

(150,967

)

 

 

(141,096

)

Total Stockholders' Equity

 

 

18,363

 

 

 

27,558

 

Total Liabilities and Stockholders' Equity

 

$

21,745

 

 

$

32,282

 

 

 

 

 

 

 

 

 

 

 

IN8BIO, INC.

STATEMENTS OF OPERATIONS

(In thousands, except share and per share data)

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

2,493

 

 

$

2,487

 

 

$

5,106

 

 

$

5,459

 

 

General and administrative

 

 

2,442

 

 

 

2,714

 

 

 

5,095

 

 

 

5,402

 

 

Total operating expenses

 

 

4,935

 

 

 

5,201

 

 

 

10,201

 

 

 

10,861

 

 

Interest income

 

 

154

 

 

 

107

 

 

 

330

 

 

 

217

 

 

Loss from operations

 

 

(4,781

)

 

 

(5,094

)

 

 

(9,871

)

 

 

(10,644

)

 

Net loss

 

$

(4,781

)

 

$

(5,094

)

 

$

(9,871

)

 

$

(10,644

)

 

Net loss per share – basic and diluted

 

$

(0.25

)

 

$

(1.24

)

 

$

(0.51

)

 

$

(3.65

)

 

Weighted-average number of shares used in computing net loss per common share, basic and diluted

 

 

19,467,091

 

 

 

4,119,153

 

 

 

19,468,087

 

 

 

2,920,157

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

# # #

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

2 documents

Press Releases

Other Documents